KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) EBT Margin (2016 - 2026)

Pacira BioSciences has reported EBT Margin over the past 17 years, most recently at 2.82% for Q1 2026.

  • For Q1 2026, EBT Margin fell 234.0% year-over-year to 2.82%; the TTM value through Mar 2026 reached 1.79%, up 1147.0%, while the annual FY2025 figure was 2.32%, 1133.0% up from the prior year.
  • EBT Margin for Q1 2026 was 2.82% at Pacira BioSciences, up from 0.29% in the prior quarter.
  • Over five years, EBT Margin peaked at 22.34% in Q2 2023 and troughed at 82.37% in Q3 2024.
  • A 5-year average of 1.74% and a median of 5.15% in 2025 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: plummeted -9250bps in 2024 and later surged 8768bps in 2025.
  • Year by year, EBT Margin stood at 3.77% in 2022, then skyrocketed by 394bps to 18.6% in 2023, then dropped by -27bps to 13.63% in 2024, then crashed by -98bps to 0.29% in 2025, then soared by 872bps to 2.82% in 2026.
  • Business Quant data shows EBT Margin for PCRX at 2.82% in Q1 2026, 0.29% in Q4 2025, and 5.31% in Q3 2025.